of 55
8/17/2019 Screening for Hematologic Disorders
1/55
!
" #
8/17/2019 Screening for Hematologic Disorders
2/55
$ % % &
" % " "%
'(
8/17/2019 Screening for Hematologic Disorders
3/55
!
8/17/2019 Screening for Hematologic Disorders
4/55
8/17/2019 Screening for Hematologic Disorders
5/55
Phospholipids 80%SaturatedPhosphatidylcholine 60%UnsaturatedPhosphatidylcholine 25%Phosphatidylglycerol andPhosphatidylinositol 15%
Protein 12%
Neutral Lipids 8%
8/17/2019 Screening for Hematologic Disorders
6/55
" # ( "#"
" ! # '((" )
" $ " # !
8/17/2019 Screening for Hematologic Disorders
7/55
%
8/17/2019 Screening for Hematologic Disorders
8/55
# " *+ " "
8/17/2019 Screening for Hematologic Disorders
9/55
% ,' '
- ,- . & -
- (
- & "-
8/17/2019 Screening for Hematologic Disorders
10/55
$ . ) &
' " ) ) ( & +
) " "( % + . '* ! ) /
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
11/55
" % ! " ! #
$ % " $ " ! " ! # & '( ( $ ( ( ( ) ' ! * ' "
+ # (
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
12/55
PREVENTION
!
TREATMENT
Prophylactic
PreVentilation
PostVentilation
EarlyRescue Late
Rescue
) ( 44 5 62 ( 5 1 % " 45 7 % " 44 583 %
8/17/2019 Screening for Hematologic Disorders
13/55
&' ()"(* +, 9 "( % + " (
( % ( ! (
% (# " ( # % " ( %
" 0
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
14/55
, "' ' - . /! #
" 0 0
1 ! , 1 - * 0$ " ! 2 3
$ 4 0 5)6$ - * - *
$17 ** $ " ! ’# **
8 ** **
8/17/2019 Screening for Hematologic Disorders
15/55
* ) "#" %
* " %
- + . / 0
No clinically significant difference in outcome
between immediate administration of prophylacticsurfactant and administration at 10 min after birthafter a brief period of stabilization
8/17/2019 Screening for Hematologic Disorders
16/55
↓↓↓↓
, 12 ↓↓↓↓ . $ !
, 1: ↓↓↓↓ /
, :2 ↓↓↓↓ %1
, 66
An ounce ofprevention isbetter than a
pound of cure !!
2 0
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
17/55
Early surfactant with brief ventilation Vsselective surfactant and MV for pretermwith or at risk for RDS
' 0 %- ;- 0 - 0 9 (
8/17/2019 Screening for Hematologic Disorders
18/55
7 / " ! (! 9 6 : 5
* ( # # # !( * % ( " ( $1
7 ! #! " ! (! 9 6 ( ; 5 / ( (( / !
( (% * $17
8/17/2019 Screening for Hematologic Disorders
19/55
+
' 0 % "
9 ) ) )
) (
' ( " + 0% % % "" "
% " (
8/17/2019 Screening for Hematologic Disorders
20/55
= + '' ! - (
" - > " ' .
- 2' ( > * (
! # ?
8/17/2019 Screening for Hematologic Disorders
21/55
↓↓↓↓
, 12 ↓↓↓↓ . $ !
, ?7
↓↓↓↓ / 3 %1 , ?? ! 3 )
↓↓↓↓ ! 3 %2- , ?@ ! 1: )
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
22/55
↓↓↓↓ / , 7
/$ !%2-
!
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
23/55
. 01 &'* ,
↓↓↓↓ / , 12
↓↓↓↓ %1
, ?7 ↓↓↓↓
, 66 ↓↓↓↓ 4!
, 66
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
24/55
( ) ) " ) ' " ) " "
A % " *+ " A % " + B/8 ; "
8/17/2019 Screening for Hematologic Disorders
25/55
5 0
% " ) % (! ) &
* ( ) ( 0 % " " C & >" ( ) " 0 "( %
0 %
.
, ! 1 - ( & ( ) 3
@ 0 ,1
8/17/2019 Screening for Hematologic Disorders
26/55
& ". .,
- - %
" , ( " - '(("
- ' ( " " - * % .& " . " "
A 9 , $ 3 A 0 0 5 33
8/17/2019 Screening for Hematologic Disorders
27/55
--8-" +/"
& ") 8 (
?:"
: (*+ "
(
& "1? 1:-1 :"
? 1: (" "
& "88"
8 (" )
>"!( .9
2 ? 9
8/17/2019 Screening for Hematologic Disorders
28/55
- 10C2-8 C2-8 CStorage
3/ 5 ml1.5 ml4 / 8 mlVial size
Bovine liquidPorcine lungBovine lungSource
Slowly warm toroom temp
Wait for 30min
Warm atroom temp
for 10minOr in hand
for 8 min
Gettingready
334Max. doses
5 cc/kg2.5 cc/kg4 cc/kgInitial doseYesYesYesTreatment
NoNoYesProphylaxis
NeosurfCurosurfSurvanta
8/17/2019 Screening for Hematologic Disorders
29/55
. 0
( % # " " %# ) +
( # 0 ( )" % ) % 0 % ( # 0 % ( ( ( <
" (
% " 122@D?EF?:2-?:8
8/17/2019 Screening for Hematologic Disorders
30/55
Implementation of surfactant treatmentduring CPAP (INSURE)
) ( ! * A8
6 03B * ! * ( C # ;0 (* ( *
7 ' " ** )1&.' ( # /!
(* ( (( ' A8
! D . @ $ 3 @ 3 3 3
8/17/2019 Screening for Hematologic Disorders
31/55
6 .
*,, # " ; " ; "
0 " ) *,,
G
8/17/2019 Screening for Hematologic Disorders
32/55
5 . 0
% ( (% + (
% "
"
8/17/2019 Screening for Hematologic Disorders
33/55
7 2 .
,0 # %
( ( % % %
# % 0 % ) #
% # ( & ) 0 1223
8/17/2019 Screening for Hematologic Disorders
34/55
" & ) + #
& - ( % " # F
- " + >" ( 62 (- % 1 >" ( # 7 %
- "# ?1 % ( % - . 5 2 11
8/17/2019 Screening for Hematologic Disorders
35/55
2 .
& % I "
0 # " " " + (
A % % " ; #(( + "#
8/17/2019 Screening for Hematologic Disorders
36/55
, 0 # "
& 9 " ( "( . % ( %
% # "
'(("
8/17/2019 Screening for Hematologic Disorders
37/55
.
/"
8/17/2019 Screening for Hematologic Disorders
38/55
"$ % %
' " ) ) 5 ?1:2 (
" )
)
A #* A 4 " 1 9 - 0 5 05
8/17/2019 Screening for Hematologic Disorders
39/55
! "( (
"(
" ( % ( %
% " (
% ( %
8/17/2019 Screening for Hematologic Disorders
40/55
. *+ ( % 0 % % (
# 5 68 0 9 % " # ) " . "
) #
(#
" ( ) " "( % % (
8/17/2019 Screening for Hematologic Disorders
41/55
( " %
% " "( # 1@C13 0 9 J
''
"
( )" ( % ) ( 9 (
''
.
8/17/2019 Screening for Hematologic Disorders
42/55
1990 2006
Exosurf Survanta Infasurf Curosurf1991 1998 1999
Surfaxin
Animal derived proteincontaining surfactants
In two trials of protein containing synthetic surfactants
compared to animal derived surfactant extract,no statistically different clinical differencesin death and chronic lung disease were noted.
Cochrane Database Syst Rev. 2008
8/17/2019 Screening for Hematologic Disorders
43/55
% ( )
) ) " %9 &
' " % % 9 (
(# " ) !
E7 4 # . $ ( 8 0 0 9 -
8/17/2019 Screening for Hematologic Disorders
44/55
# G C % " # "" " % ( ) "
% % " (
% "
,% # # % " # ( #< )
%
8/17/2019 Screening for Hematologic Disorders
45/55
,% % " & "
) % % ) ;
% " % # " % #" ( # # "
% # ) " G
% ( - ) % "( ) " ( &
%
8/17/2019 Screening for Hematologic Disorders
46/55
* " % # %
" % " # ( # # 0& 0% 1 8 ( 7 ( 0% )
& 0 + "# " (
%
8/17/2019 Screening for Hematologic Disorders
47/55
%
,% ) % + # ) ( ( ( % 1
0 % 0 % " + " "( " % "
0 % " ( # '' #
8/17/2019 Screening for Hematologic Disorders
48/55
+ .
8 . . *
.
% %9 9
%72 9 5 5
8/17/2019 Screening for Hematologic Disorders
49/55
Thermoregulation Infection
Nutrition
R D S
Hostresponse
Ventilation
Supportivecare
8/17/2019 Screening for Hematologic Disorders
50/55
8/17/2019 Screening for Hematologic Disorders
51/55
U i i b bbl i i
8/17/2019 Screening for Hematologic Disorders
52/55
Using microbubble test in gastric
aspirates for surfactant ( < 31 w) 5 " - -- ( A >"" ' '!( * F ; G 5 A >"" # (
! ' 55B ! / A ' '! ( *
* ( / ! ! #! A C( ! ' # ' B , 0 B
B * ( - : / %( *# ( B * ( - /
0 / %( ( *
9 @ $ A 0 3
8/17/2019 Screening for Hematologic Disorders
53/55
9 /
/ * 0 # # % (-( %+ % " " )
% % :2 H % ? : H! ? H
:2 ( .9 ( (
1 ( & :22.
D' K & ?EE3 D?2@F??6-@
%
8/17/2019 Screening for Hematologic Disorders
54/55
% . (
'( ) " ) ) ( & # #
(
(
< )
1228
.
8/17/2019 Screening for Hematologic Disorders
55/55
*+ " " , ( ( 8: (